Used in cancer immunotherapy to target B7-H3 (CD276), a protein overexpressed in various solid tumors including prostate, breast, lung, and pediatric cancers. This reference antibody serves as a critical tool for developing diagnostic assays and therapeutic antibodies. It enables precise detection and quantification of B7-H3 expression in tumor tissues, supporting patient stratification and treatment monitoring. Due to its high specificity, it is also employed in the development of antibody-drug conjugates (ADCs), bispecific antibodies, and CAR-T cell therapies aimed at enhancing anti-tumor immune responses. Its role in preclinical research helps validate B7-H3 as a therapeutic target and supports the optimization of novel immuno-oncology agents.